Indeed, inhibition of ODC1 with difluoromethylornithine (DFMO) is suggested to reduce the risk of colorectal cancer26 and targeting AMD1 with SAM486A reduces prostate cancer growth with negligible systemic toxic effects22. The gene discussed is ODC1; the disease is prostate cancer.